Biogen stock
Price history
+53.83% over the period1 year: from $164.73 (November 13, 2025) to $253.40 (November 13, 2026), +53.83%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 13, 2026 | $253.40 |
| October 30, 2026 | $253.62 |
| September 30, 2026 | $225.88 |
| August 31, 2026 | $216.65 |
| July 31, 2026 | $202.95 |
| June 30, 2026 | $216.06 |
| May 29, 2026 | $196.00 |
| April 30, 2026 | $189.28 |
| March 31, 2026 | $183.33 |
| February 27, 2026 | $191.82 |
| January 30, 2026 | $179.89 |
| December 31, 2025 | $175.99 |
| November 28, 2025 | $182.09 |
| November 13, 2025 | $164.73 |
At a glance
The company
Discovers, develops, manufactures and delivers therapies for multiple sclerosis, neurological disorders, cancer, immunology and other conditions
Latest results
Quarter to September 30, 2026 · EPS $2.62 (estimate $2.02)
TickerLandia's take on Biogen
- Pricier than usual relative to earnings: P/E on the latest fiscal year 29 vs a median of 15 over its last 10 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 108 vs 42 (+156%) in a group of 10.
- Strong point: Market momentum (89/100 in its group). Weak point: Profitability (28/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−2.91% from the 52-week high
Analysts · 36 analysts
Average target$268.26+5.86% vs. price
Buy 25 · Hold 10 · Sell 1 · Buy
TickerLandia Fingerprint: Biogen
Compared with similar companies: very strong momentum.
Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 883 North American stocks.
Priceaverage54
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 108.3 93 Forward P/E 15.6 44 EV/EBITDA 13.3 62 Price/book 1.98 19 Price/sales 3.64 50 Profitabilitylow28
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 75.8% 78 Net margin 3.4% 10 ROE 1.9% 10 ROA 4.9% 14 Operating margin 23.5% 26 Earnings stabilityaverage56
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 4.1% 58 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 54 Growthlow30
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) −0.94% 18 Revenue growth (year over year) +10.60% 66 Earnings growth (year over year) −84.76% 6 Financial strengthaverage57
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 1.01 54 Interest coverage 10.6 34 Current ratio 1.95 74 Debt/equitycounts in reverse: lower means more financial strength 0.41 65 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery strong89
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +24.07% 95 1-year return +53.83% 89 Distance from 200-day average +23.52% 91 Relative strength (6 months) +21.97% 80 Risklow26
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 14.3% 8 Volatility (60 days) 28.2% 33 Beta (1 year) 0.42 37
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Biogen is pricier than in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), Biogen's P/E today is 28.8, above the median of its last 10 fiscal years (15.3; between 9.44 and 32.5 from 2016 to 2025). Biogen's P/E (trailing 12 months): 108.3, +156% against the median of a group of 10 similar companies (42.3).
Compared with 10 similar companies
| Metric | Biogen | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 108.3 | High | |
| Forward P/E | 15.6 | Low | |
| Operating margin | 23.5% | Low | |
| ROE | 1.9% | Low | |
| Debt/equity | 0.41 | Low |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Biogen. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$2.74B
Latest quarter · Q2 2026
Net income
$97.5M
Latest quarter · Q2 2026
Quarterly net margin
3.6%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $37.46B
- P/E
- 108.3
- EPS
- $2.34
- Volume
- 1.03M
- Daily trading
- €277.08M
How Biogen is changing
All resultsRevenue fell 6.0% a year on average over the last 5 years
Profits turn into cash: free cash flow equal to 148% of net income
Shares outstanding down 8.8% in 5 years
Returns
Biogen returns with dividends
$1,000 invested in Biogen 5 years ago, on November 15, 2021, would be worth $932 today with dividends reinvested: −6.78% in total, −1.40% per year. On price alone it would be $932 (−6.78%).
| Period | Biogen | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +10.70% | −3.12% | $1,107 |
| 6 months | +23.89% | +1.58% | $1,239 |
| Year to date | +43.99% | +10.46% | $1,440 |
| 1 year | +53.83% | +12.23% | $1,538 |
| 3 years | +13.84% | +71.41% | $1,138 |
| 5 years | −6.78% | +61.48% | $932 |
| 10 years | −14.55% | +249.40% | $855 |
Over the last 6 months it has done better than 60% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment
The chart in detail
Biogen: technical analysis
Biogen is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 46.8% below its all-time closing high ($475.98, March 20, 2015).
- Trend
- Upward
- RSI (14 sessions)
- 59
- Between 30 and 70
- vs 200-session average
- +23.52%
Support and resistance
Price areas where Biogen has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price$253.40
- Support$224.33−11.47%2 touches, last on September 3, 2026
- Support$217.46−14.18%4 touches, last on October 8, 2026
- Support$207.45−18.13%2 touches, last on September 10, 2026
Volatility and risk
Over the last year it has moved less than the S&P 500.
- Beta (1 year) vs S&P 500
- 0.42
- Volatility (60 sessions, annualised)
- 28.2%
- Largest fall in the last year
- −14.34%
Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Biogen: seasonality
Average monthly price change over 36 years
Over the last 36 years, the strongest month for Biogen has been October: +6.06% on average, positive in 20 years out of 36. The weakest has been March: −2.40% on average, positive in 16 years out of 35. November, the current month, has been positive in 21 years out of 35 (+1.82% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +3.93% | +2.22% | 20 of 35 |
| February | −0.28% | −1.73% | 15 of 35 |
| March | −2.40% | −0.19% | 16 of 35 |
| April | −1.96% | −1.62% | 12 of 35 |
| May | +3.35% | +3.55% | 22 of 35 |
| June | +1.90% | −0.66% | 17 of 35 |
| July | +3.20% | +2.67% | 23 of 35 |
| August | +3.18% | +2.84% | 21 of 35 |
| September | +2.37% | +0.64% | 18 of 35 |
| October | +6.06% | +4.24% | 20 of 36 |
| November | +1.82% | +3.37% | 21 of 35 |
| December | +3.42% | −1.12% | 16 of 35 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Biogen and its competitors
Biogen's sales reach across the United States, Europe, Germany, Asia and other international markets, where it discovers, develops, manufactures and delivers therapies. Its portfolio centres on treatments for multiple sclerosis, including TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and OCREVUS, alongside SPINRAZA for spinal muscular atrophy, SKYCLARYS for Friedreich's Ataxia, QALSODY for amyotrophic lateral sclerosis and LEQEMBI for Alzheimer's disease. The company also sells biosimilars of ENBREL, HUMIRA and REMICADE, anti-CD20 lymphoma and leukemia therapies such as RITUXAN and GAZYVA, and ZURZUVAE for postpartum depression.
- Headquarters
- Cambridge, United States
- Employees
- 7,500
- Founded
- 1978
- Chief executive
- Christopher Viehbacher
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| BiogenBIIB | $37.46B | 23.5% | 108.3 | +23.89% |
| Bristol-Myers SquibbBMY | $129.66B | 32.4% | 14.1 | +12.48% |
| PfizerPFE | $164.67B | 29.1% | 41.3 | +11.29% |
| Gilead SciencesGILD | $208.48B | 38.2% | — | +26.33% |
| AmgenAMGN | $251.89B | 34.1% | 27.0 | +38.41% |
| MerckMRK | $364.26B | 35.2% | 147.8 | +30.24% |
Same industry or related industries, similar size. Compare Biogen with its competitors · Full profile
